Aadi BioscienceAADI
AADI
About: Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Employees: 53
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
309% more call options, than puts
Call options by funds: $94K | Put options by funds: $23K
100% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]
91% more capital invested
Capital invested by funds: $24.7M [Q3] → $47.2M (+$22.5M) [Q4]
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
11.97% more ownership
Funds ownership: 48.66% [Q3] → 60.63% (+11.97%) [Q4]
2% more funds holding
Funds holding: 52 [Q3] → 53 (+1) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
Research analyst outlook
We haven’t received any recent analyst ratings for AADI.
Financial journalist opinion
Based on 6 articles about AADI published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Aadi Bioscience, Inc. (AADI) Expected to Beat Earnings Estimates: Should You Buy?
Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
PRNewsWire
1 week ago
Aadi Bioscience Announces Closing of $100 Million PIPE Financing
MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement.
Neutral
PRNewsWire
1 week ago
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025.
Positive
Zacks Investment Research
2 weeks ago
All You Need to Know About Aadi Bioscience (AADI) Rating Upgrade to Buy
Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
PRNewsWire
2 weeks ago
Aadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
MORRISTOWN, N.J. , Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA.
Neutral
PRNewsWire
3 weeks ago
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J. , Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO).
Neutral
PRNewsWire
1 month ago
Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025
Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends Stockholders Vote "FOR" All Proposals to Support the Company's Business Transformation Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions MORRISTOWN, N.J. , Feb. 5, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") which is scheduled to be held on February 28, 2025.
Positive
Benzinga
2 months ago
Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.
Neutral
PRNewsWire
2 months ago
Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and HANGZHOU DAC BIOTECHNOLOGY CO., LTD. (HANGZHOU DAC), a global leader in ADC innovation.
Neutral
Zacks Investment Research
4 months ago
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates
Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.46 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.
Charts implemented using Lightweight Charts™